Table 1.
Patient baseline characteristics
| Characteristic | Czech Republic (N = 300) | Slovakia (N = 300) | Overall (N = 600) |
|---|---|---|---|
| Age (years) | |||
| n | 300 | 300 | 600 |
| Mean (SD) | 69.0 (8.7) | 64.3 (8.6) | 66.7 (9.0) |
| Body mass index (kg/m2) | |||
| n | 296 | 268 | 564 |
| Mean (SD) | 25.4 (4.3) | 26.8 (4.7) | 26.1 (4.6) |
| Age at menopause (years) | |||
| n | 300 | 300 | 600 |
| Mean (SD) | 48.3 (5.6) | 48.3 (5.2) | 48.3 (5.4) |
| Median (Q1, Q3) | 50.0 (46.0, 52.0) | 50.0 (45.0, 52.0) | 50.0 (45.0, 52.0) |
| Years since menopause | |||
| n | 300 | 300 | 600 |
| Mean (SD) | 20.7 (9.2) | 15.9 (9.4) | 18.3 (9.6) |
| Median (Q1, Q3) | 21.0 (13.5, 28.0) | 15.0 (9.0, 22.0) | 17.0 (11.0, 25.0) |
| Cause of menopause, n (%) | |||
| Natural onset | 248 (82.7) | 244 (81.3) | 492 (82.0) |
| Clinically/surgically induced | 51 (17.0) | 53 (17.7) | 104 (17.3) |
| Unknown | 1 (0.3) | 3 (1.0) | 4 (0.7) |
| Time since PMO diagnosis (years) | |||
| n | 300 | 300 | 600 |
| Mean (SD) | 5.3 (5.2) | 3.0 (4.7) | 4.1 (4.8) |
| Median (Q1, Q3) | 4.7 (0.7, 8.2) | 1.0 (0.1, 4.6) | 2.6 (0.2, 6.8) |
| Any historical fracture, n (%) | 221 (73.7) | 100 (33.3) | 321 (53.5) |
| Osteoporotica | 203 (67.7) | 90 (30.0) | 293 (48.8) |
| Vertebral | 93 (31.0) | 21 (7.0) | 114 (19.0) |
| Non-vertebral | 153 (51.0) | 74 (24.7) | 227 (37.8) |
| Major non-vertebralb | 119 (39.7) | 62 (20.7) | 181 (30.2) |
| Hip | 18 (6.0) | 5 (1.7) | 23 (3.8) |
| At least two previous fractures, n (%) | 97 (32.3) | 21 (7.0) | 118 (19.7) |
| Hospitalized for osteoporotic fracture, n (%) | |||
| Yes | 63 (21.0) | 11 (3.7) | 74 (12.3) |
| No | 237 (79.0) | 289 (96.3) | 526 (87.7) |
| At least one fall in previous 12 months, n (%) | |||
| Yes | 61 (20.3) | 24 (8.0) | 85 (14.2) |
| No | 239 (79.7) | 276 (92.0) | 515 (85.8) |
| At least one occurrence of immobility in the previous 12 months, n (%) | |||
| Yes | 19 (6.3) | 6 (2.0) | 25 (4.2) |
| No | 281 (93.7) | 294 (98.0) | 575 (95.8) |
| Previous exposure to PMO therapy, n (%) | |||
| Yes | 255 (85.0) | 146 (48.7) | 401 (66.8) |
| No | 45 (15.0) | 154 (51.3) | 199 (33.2) |
| Exposure to PMO therapy in the previous 12 months, n (%) | |||
| Yes | 240 (80.0) | 119 (39.7) | 359 (59.8) |
| No | 60 (20.0) | 181 (60.3) | 241 (40.2) |
| Previous exposure to calcium and/or vitamin D supplements, n (%) | |||
| Yes | 151 (50.3) | 19 (6.3) | 170 (28.3) |
| No | 149 (49.7) | 281 (93.7) | 430 (71.7) |
| Secondary osteoporosis, n (%) | |||
| Yes | 45 (15.0) | 23 (7.7) | 68 (11.3) |
| No | 255 (85.0) | 277 (92.3) | 532 (88.7) |
| Presence of at least one comorbidity, n (%) | 290 (96.7) | 272 (90.7) | 562 (93.7) |
| Modified Wolfe comorbidity index | |||
| n | 300 | 300 | 600 |
| Mean (SD) | 1.9 (1.5) | 1.4 (1.2) | 1.6 (1.4) |
PMO postmenopausal osteoporosis, Q quarter, SD standard deviation
aAny fracture recorded on the clinical record form not including skull, facial bones, fingers, and toes and not associated with known high trauma severity or pathologic fractures
bA subset of non-vertebral fractures including those at the following locations: pelvis, hip, upper leg (not hip), lower leg (not knee or ankle), ribs, shoulder, forearm, and wrist and not associated with known high trauma severity or pathologic fractures